Interchangeable biosimilars to Prolia and Xgeva target osteoporosis and cancer-related bone complications in a $5 billion U.S. market
The drug meets all primary endpoints across 608 patients in Europe and India, strengthening the company's biosimilars pipeline
India’s first prospective study finds molecular testing improved diagnostic clarity in 50% of complex sarcoma cases
The JADE trial enrolled 164 U.S. patients who initially received three monthly doses of OLN324 or faricimab, followed by 12 weeks off treatment with retreatment allowed only if disease recurred
Key FDA decisions and pivotal late-stage obesity and breast cancer data could reshape competitive positioning
The move comes as China rapidly expands its capabilities in the pharmaceutical sector, particularly in licensing and drug development
Indomo’s ClearPen system combines a proprietary self-injection device and microneedle with a modernized triamcinolone acetonide formulation
To support this launch, ImmunityBio has established a wholly owned subsidiary in Saudi Arabia
A final tranche of €12 million will follow, contingent on positive pivotal study results, with the share price calculated according to an agreed formula
Achondroplasia is a genetic condition driven by FGFR3 that affects more than stature alone
This deal marks a major step for Alteogen as it pushes its Hybrozyme platform deeper into the oncology market
InflaRx is streamlining operations and largely discontinuing non-essential activities outside izicopan’s development
The partnership aims to develop a first-in-class broad-spectrum antifungal to combat life-threatening invasive infections
This drug candidate, which is currently progressing through pivotal clinical studies, has the potential to become the first add-on therapy for schizophrenia patients who do not respond adequately
SLE remains a life-threatening autoimmune disease, with patients facing an elevated risk of early mortality and long-term organ damage
Heart failure affects an estimated 64.3 million people worldwide
Kelun-Biotech and Crescent Biopharma forged a collaboration covering SKB105/CR-003 and SKB118, a PD-1 x VEGF bispecific antibody also known as CR-001
The resubmission of BLA for MOLBREEVI names Fujifilm as the drug substance manufacturer
The new single-use commercial facility will be among India’s largest, featuring advanced technologies to produce high-quality biologics and specialty pharmaceuticals
Subscribe To Our Newsletter & Stay Updated
